Genpact Cora: How Pharma Leaders Are Cutting PV Costs by 40% with AI
Overview: How Genpact Cora’s AI-Driven Pharmacovigilance Platform Transforms Drug Safety Monitoring Genpact Cora is an AI-powered pharmacovigilance platform that automates end-to-end adverse-event case processing, safety-signal detection, and regulatory-reporting workflows for pharmaceutical and biotechnology companies. It addresses a critical bottleneck in drug safety operations: the labour-intensive, manual extraction and coding of adverse event data from unstructured […]
Feature Categories
Overview: How Genpact Cora's AI-Driven Pharmacovigilance Platform Transforms Drug Safety Monitoring
Genpact Cora is an AI-powered pharmacovigilance platform that automates end-to-end adverse-event case processing, safety-signal detection, and regulatory-reporting workflows for pharmaceutical and biotechnology companies. It addresses a critical bottleneck in drug safety operations: the labour-intensive, manual extraction and coding of adverse event data from unstructured sources such as call centre transcripts, medical literature, social media, and healthcare provider reports, which creates processing delays, increases error rates, and limits the ability to detect emerging safety signals in real time across global markets.
The platform uses natural language processing, optical character recognition, machine learning, and robotic process automation to automatically extract, standardise, and code adverse event information from diverse data sources into structured case reports aligned with regulatory requirements. By automating case intake, triage, data entry, and MedDRA coding tasks that traditionally require manual review, Genpact Cora transforms unstructured safety data into actionable insights while continuously learning from processed cases to improve accuracy and develop predictive analytics capabilities. The system integrates rule-based compliance workflows with AI-driven signal detection algorithms to identify safety trends and potential risks earlier in the drug lifecycle.
In practice, Genpact Cora streamlines workflows for pharmacovigilance teams by reducing case processing time and manual effort, enabling safety officers to focus on clinical assessment and risk evaluation rather than administrative data entry. Organisations benefit from increased case throughput, improved compliance with evolving global pharmacovigilance regulations, and enhanced ability to detect safety signals proactively through predictive analytics. Industry implementations have demonstrated significant operational improvements, with pharmaceutical companies reporting up to 40 percent reductions in pharmacovigilance costs while maintaining regulatory compliance and improving patient safety outcomes.
Last checked May 6, 2026: Platform remains active with Cora Orchestration 10.8 released (Sept 2025); Genpact acquired XponentL Data for $159.8M (June 2025) to enhance AI and data capabilities including life sciences expertise. Named ISG Leader in GenAI & Agentic AI (Dec 2025). Platform expanding into agentic AI solutions across multiple industries while maintaining pharmacovigilance capabilities with enterprise pharma customers.
What is Genpact Cora?
Genpact Cora is an AI-powered pharmacovigilance platform that automates end-to-end adverse event case processing, including case intake, data extraction from unstructured sources, MedDRA coding, regulatory report generation, and safety signal detection for pharmaceutical and biotechnology companies. It is designed for drug safety teams, pharmacovigilance officers, and regulatory affairs departments within life sciences organisations conducting post-marketing surveillance and clinical safety monitoring. The platform differentiates itself through integrated natural language processing, optical character recognition, robotic process automation, and machine learning that automates up to 70 per cent of manual data collection tasks, enabling predictive analytics for proactive safety signal detection; it has been deployed by major pharmaceutical companies, including Eli Lilly, AstraZeneca, GSK, and Bayer, for enterprise-scale pharmacovigilance operations.
Why Do Leading Healthcare Teams Trust Genpact Cora?
-
Strategic co-innovation partnership with Bayer announced in 2018 to develop AI capabilities specifically for patient safety and pharmacovigilance workflows.
-
Deployed by major global pharmaceutical companies, including Eli Lilly, AstraZeneca, GlaxoSmithKline (GSK), and Bayer, for enterprise-scale pharmacovigilance operations.
-
Awarded U.S. Patent for Natural Language Understanding Technology Framework in 2018, demonstrating intellectual property protection and technical innovation in AI-driven safety monitoring.
-
Part of Genpact's enterprise AI platform launched in 2017, backed by a publicly traded company with an established presence in life sciences business process management and regulatory compliance services.
-
Designed to support global pharmacovigilance regulatory compliance, including FDA, EMA, and ICH guidelines for adverse event reporting and safety signal detection.
-
Processes over 70 per cent of manual data collection tasks through automated extraction, coding, and case processing, demonstrating production-scale validation in regulated environments.
-
Integrated with existing safety databases and regulatory reporting systems used by pharmaceutical companies for end-to-end case management and submission workflows.
-
Genpact has accelerated its strategy to establish industry standards for AI-driven pharmacovigilance through partnerships and patent development since 2018.
-
Platform combines multiple AI technologies, including natural language processing, optical character recognition, robotic process automation, and machine learning, with rule-based compliance workflows for audit-ready outputs.
-
Validated through real-world implementations showing up to 40 per cent cost reductions in pharmacovigilance operations while maintaining regulatory compliance and improving safety signal detection capabilities.
Evaluation Snapshot
When safety, regulatory, and IT leaders evaluate the research company Genpact on life sciences capabilities, they assess Genpact Cora as an enterprise artificial intelligence and automation platform tailored for high-volume pharmacovigilance (PV) and drug safety surveillance.
Evidence and credibility: Public evidence is reasonably strong for operational PV automation. Published research signals are limited on the reviewed pages, but customer deployments and product claims are visible, including PVAI/Cora use in adverse-event case processing, case intake, MedDRA coding, and regulatory reporting. Third-party validation exists in analyst recognition and competitive assessments, but no independent clinical validation studies on patient outcomes were found. The vendor does not publish outcome data on the reviewed pages, so reported automation and cost-reduction figures should be treated as vendor- or customer-reported rather than independently verified.
Trust and stability: Company status: ACTIVE. Genpact is a publicly traded enterprise services and technology company with long life sciences experience. No acquisition or ownership change was stated in the sources reviewed, although Genpact has continued to expand its life sciences and AI portfolio; recent materials also show active recognition from analyst firms and ongoing platform development.
Workflow fit: Primary workflow: pharmacovigilance operations, especially ICSR intake, case processing, signal detection support, and regulatory submission handling. Target users: pharmacovigilance operations teams, safety scientists, and regulatory affairs specialists. Integration surface: enterprise safety databases and global safety workflows; deployment model is enterprise and process-integrated rather than point-of-care. Implementation complexity: HIGH.media.
Technical approach: AI / ML approach: NLP, OCR, RPA, and machine learning for unstructured safety-data extraction and workflow automation. Automation depth appears high, with reports of substantial automation in manual case-processing tasks, while human oversight remains part of the model because safety specialists review and validate outputs before submission. Explainability details are not clearly stated on the reviewed pages.media.
Limitations: Independent outcome evidence is limited; healthcare-specific compliance posture is described in broad terms rather than with detailed validation documentation; integration and CSV/GxP overhead will likely need careful buyer review.
Practical assessment: A cautious buyer should view Genpact Cora as a credible enterprise automation option for pharmacovigilance operations, but one that warrants detailed validation of integrations, controls, and regulatory readiness before deployment.
Top 3 Pain Points Genpact Cora Fixes in Healthcare
| Problem | How Genpact Cora PV Solves It |
|---|---|
| 1. Manual & Time-Consuming Case Processing | Automates case intake, triage, and data entry using AI and NLP, reducing processing time and human errors. |
| 2. Compliance Risks Across Global Regulations | Ensures real-time adherence to evolving pharmacovigilance regulations with automated rule-based workflows. |
| 3. Limited Insights from Adverse Event Data | Uses predictive analytics to detect safety signals earlier, improving decision-making and patient safety outcomes. |
Feature Category Summary: Genpact Cora
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | Genpact describes its PVAI/Cora PharmacoVigilance solution as delivering “100 percent regulatory compliance” for drug safety operations and transforming PV from tracking to predicting issues, with automation of regulatory reports and end‑to‑end compliance with global pharmacovigilance regulations; descriptions emphasize audit readiness and standardized processes, but there is no public evidence of formal FDA/EMA software clearance or detailed 21 CFR Part 11 validation documentation. Explicit claims of full regulatory compliance and auditability for PV workflows support classifying it as regulatory‑ready at the process level, though not as a regulated medical device. | YES |
| Clinical Trial Support | PVAI is positioned around post‑marketing and clinical safety surveillance, automatically processing ICSRs and other safety data to identify and analyze patient safety trends, and Genpact materials note that Cora pharmacovigilance helps detect new side effects earlier and improve patient safety; however, public documentation does not explicitly describe support for trial design, protocol optimization, site selection, or recruitment, and focuses instead on ongoing safety monitoring and regulatory reporting. Because clinical‑trial specific design or recruitment features are not clearly documented, this cannot be confirmed as a primary clinical‑trial support tool. | NA |
| Supply Chain & Quality | Cora PharmacoVigilance is designed for safety case processing and signal detection, not for manufacturing QA or supply chain traceability; Genpact’s broader regulatory and RA content references supply‑chain tracking and CMC compliance at an advisory level, but there is no indication that Cora PVAI manages batch release, counterfeit detection, serialization, or GMP quality event workflows. “No public documentation found” linking the PV product itself to supply chain or manufacturing‑quality management features. | NA |
| Efficiency & Cost-Saving | Genpact states that its PVAI/Cora PV solution uses OCR, NLP, and RPA to automate up to 70% of data collection for reports, significantly speeding case processing and generation of regulatory reports, and reducing human error and operational costs; case examples describe faster safety reviews, better process visibility, and substantial efficiency gains in PV teams. These are explicit claims that the platform improves efficiency and reduces cost and manual effort in pharmacovigilance operations. | YES |
| Scalable / Enterprise-Grade | Genpact positions Cora as an AI‑based digital‑transformation platform with modular components deployed across many industries, noting that Cora has been adopted by 200+ global enterprises and that major pharma companies, including top global firms such as Bayer and AstraZeneca, use Genpact Cora PharmacoVigilance for large‑scale safety operations. This demonstrates enterprise‑grade scalability and deployment in large pharma/biotech organizations. | YES |
| HIPAA Compliant | Genpact’s healthcare and life‑sciences materials highlight data security, privacy, and regulatory compliance in general, but public descriptions of Cora PharmacoVigilance and PVAI do not explicitly state “HIPAA compliant” or reference HIPAA/HITECH‑specific controls for PHI; the emphasis is on pharmacovigilance regulations and global safety reporting rather than U.S. healthcare privacy law. “No public documentation found” with a clear HIPAA compliance statement for Cora PV, so HIPAA compliance cannot be validated. | NA |
| Clinically Validated | While Genpact reports that PVAI/Cora PharmacoVigilance is used by top pharma companies and improves safety monitoring, there is no public evidence of formal clinical validation studies (e.g., prospective trials demonstrating improved patient outcomes attributable to the software) or FDA device‑level evaluation; references focus on operational performance and regulatory compliance rather than clinical validation as a medical product. “No public documentation found” for clinical validation in the sense of regulated clinical efficacy trials. | NA |
| EHR Integration | Descriptions of Cora PVAI emphasize ingestion of safety data from multiple sources (e.g., ICSRs, documents, faxes, scanned forms, and other structured/unstructured sources) and automated population of safety databases using RPA, but do not specifically mention direct integration with EHR/EMR systems or standards such as HL7 or FHIR; the architecture is described around OCR and data pipelines rather than embedded EHR connectors. “No public documentation found” for EHR integration, so this feature cannot be confirmed. | NO |
| Explainable AI | The Cora platform is described as using AI, analytics, and predictive modelling with a “command and control hub” that provides governance over digital workers and reduces risk from misapplied AI, and industry write‑ups note standardized workflows and audit readiness, but there is no detailed description of model‑level explainability (e.g., feature attributions or interpretable signal scores) in the PVAI safety models. “No public documentation found” for explicit explainable‑AI tooling in the pharmacovigilance component. | NA |
| Real-Time Analytics | Genpact notes that Cora enables real‑time or near‑real‑time analytics in other domains (e.g., Cora LiveWealth and Cora Data Foundation provide real‑time or same‑day analytics on data streams), and PVAI is framed as allowing earlier detection of safety trends within large data volumes, but there is no explicit statement that the PV module itself offers continuous real‑time safety dashboards or streaming analytics; the messaging is more about faster processing and earlier signal detection than strict real‑time monitoring. Because real‑time analytics in PV are not clearly documented, this cannot be validated. | NA |
| Bias Detection | Available materials describe PVAI’s use of NLP and analytics to process and analyze patient safety data, but do not discuss algorithmic bias detection, fairness metrics, or demographic subgroup performance analysis in adverse event detection models; discussions of AI in PV focus on volume and efficiency rather than equity or bias mitigation. “No public documentation found” for bias‑detection capabilities in the pharmacovigilance solution. | NA |
| Ethical Safeguards | Genpact states that Cora includes an “integrated command and control hub” to govern AI and robotic processes and reduce the risk of “misapplied AI,” and PVAI is framed as improving safety and regulatory compliance, contributing to patient protection, but there is no explicit description of in‑product consent management, configurable use‑case restrictions for AI, formal human‑in‑the‑loop gating of automated decisions, or explicit AI ethics frameworks within the PV module. “No public documentation found” for dedicated AI‑specific ethical safeguard tooling beyond general governance and compliance. | NA |
Risks & Limitations: Genpact Cora
-
Predictive performance depends on the quality, completeness, and consistency of input datasets; gaps or errors may reduce model accuracy.
-
Outputs are decision-support only; human validation is required before taking operational or clinical actions.
-
Integration with proprietary ERP systems or workflow platforms may require IT configuration and validation.
-
Regulatory or compliance review is necessary when using outputs to inform patient safety monitoring or operational decisions.
-
Automated recommendations may require continuous oversight to ensure alignment with changing guidelines and business rules.
-
Scalability may be impacted by data volume, system architecture, or cross-departmental adoption constraints.
Follow HealthyData.Science on Google Search & AI
Get our latest healthcare and life science AI tool evaluations, regulatory updates, and buyer intelligence in your Google AI Overviews.
Add as Preferred SourceGet a neutral, no obligation view of whether this AI tool fits your portfolio
